

1 **Local drug delivery to the entire cochlea without breaching its boundaries**

2 Andrei N. Lukashkin^{1,2*}, Ildar I. Sadreev³, Natalia Zakharova⁴, Ian J. Russell¹, Yury M. Yarin⁵

3 ¹ Sensory Neuroscience Research Group, School of Pharmacy and Biomolecular Sciences,
4 University of Brighton, Brighton, UK

5 ² Centre for Regenerative Medicine and Devices, University of Brighton, Brighton, UK

6 ³ Faculty of Medicine, Department of Medicine, Imperial College, London, UK

7 ⁴ Otophysica, Uckfield, UK

8 ⁵ ENT practice, Dresden, Germany

9 *Correspondence: Andrei N. Lukashkin, a.lukashkin@brighton.ac.uk

10 **ABSTRACT**

11 The mammalian cochlea is one of the least accessible organs for drug delivery. Systemic
12 administration of many drugs, notably the most frequently used corticosteroids and
13 aminoglycoside antibiotics, is severely limited by the blood-labyrinth barrier. Local
14 intratympanic administration into the middle ear would be a preferable option in this case and
15 the only option for many old and newly emerging classes of drugs and therapies including local
16 anaesthetics, antioxidants, apoptosis inhibitors, neurotransmitters and their antagonists,
17 monoclonal antibodies, growth factors, signalling pathway regulators and genetic material.
18 Intratympanic administration of drugs relies on their remaining in contact with the cochlear
19 round window membrane long enough to allow their diffusion into the cochlea fluid. The
20 ability of drugs to pass through the round window does not, however, lead to their effective
21 distribution along the long and narrow cochlear spiral. This slow technique leads to steady-
22 state, base-to-apex concentration gradients that are orders of magnitude and well outside the
23 therapeutic windows for many drugs. Here we present an efficient, quick, reliable and simple
24 method that can consistently and uniformly deliver drugs along the entire length of the intact
25 cochlea within minutes without disrupting cochlear boundaries. This novel method combines
26 middle ear drug administration and cochlear pumping, through large amplitude, low-frequency
27 reciprocal oscillations of the stapes and round window. Our preliminary experiments using
28 salicylate as a model drug with well-established physiological effect demonstrate the
29 exceptionally high efficiency of the method for drug delivery to the cochlear apex. In the short
30 term, the presented method should lead to significant improvements in the efficacy and
31 reliability of currently employed drugs for the treatment of sensorineural hearing loss,

32 Menière's disease, noise-induced hearing loss, tinnitus and autoimmune inner ear disease. In
33 the longer term, the outcomes of our research should facilitate new and novel ways of
34 approaching the treatment of inner ear disorders since we have overcome the challenge of
35 delivering of therapeutics along the entire length of the cochlea.

36 INTRODUCTION

37 Reliable, efficient and uniform drug delivery into the cochlea remains an unsolved challenge
38 and is a major barrier to the prevention or treatment of inner ear disorders. The mammalian
39 cochlea is one of the least accessible organs for drug delivery (Salt and Plontke, 2009; Hao and
40 Li, 2019). Systemic administration of many drugs, notably the most frequently used
41 corticosteroids and aminoglycoside antibiotics, is severely limited by the blood-labyrinth
42 barrier (Salt and Hirose, 2018; Nyberg et al., 2019). Direct injection into the cochlea is limited
43 by the requirement for surgical interventions, and, significantly, does not guarantee uniform
44 drug delivery along the cochlea.

45 There has been an increase in the number of therapeutic compounds with potential to treat inner
46 ear disorders. This comprises old and newly emerging classes of drugs and therapies including
47 corticosteroids, local anaesthetics, antioxidants, apoptosis inhibitors, neurotransmitters and
48 their antagonists, monoclonal antibodies, growth factors, signalling pathway regulators and
49 genetic material (Hao and Li, 2019; Devare et al., 2018). A recent review identified 43 biotech
50 companies currently pursuing experimental compounds for inner ear therapy (Schilder et al.,
51 2019). All such efforts depend on a technique allowing reliable delivery of such compounds
52 uniformly along the entire length of the cochlea.

53 Intratympanic administration of drugs (Schuknecht, 1956; Patel et al., 2019; Rybak et al., 2019)
54 relies on their remaining in contact with the round window membrane (RW, a membranous
55 opening in the bony wall of the cochlear into the middle ear) long enough to enable their
56 diffusion into the perilymph of the scala tympani (ST) (**Figure 1A**). The ability of drugs to
57 pass through the RW does not, however, guarantee their effective distribution along the
58 cochlear spiral. Drug distribution in the ST is limited by the low flow rate of perilymph within
59 the cochlea (Ohyama et al., 1988) and is dominated by passive diffusion which is constrained
60 by cochlear geometry (**Figure 1A**).

61 Combined direct measurements, morphological studies and computer modelling revealed that
62 the difference in concentration of drugs between the cochlear base and apex was many orders

63 of magnitude when drugs entered the ST through the RW and diffused passively to the apex
64 (Saijo and Kimura, 1984; Salt and Ma, 2001; Imamura and Adams, 2003; Mynatt et al., 2006;
65 Plontke et al., 2007; Plontke et al., 2008; Grewal et al., 2013; Borkholder et al., 2014; Creber
66 et al., 2018). Retention of drugs near the RW in the middle ear cavity for an arbitrary long time
67 (Piu and Bishop, 2019), once thought to be a means of overcoming the large concentration
68 gradients, does not decrease concentration gradients along the cochlea. It only stabilizes them
69 (Sadreev et al., 2019). Here we show that the same characteristics of the cochlear geometry
70 that restricts passive basal-apical diffusion, together with cochlear hydrodynamics, promotes
71 the even distribution of substances along the entire cochlear length. This enables drugs to reach
72 apical cochlear regions essential for communication and localization (Nuttall et al., 2018).

73 **Methods**

74 **Animals**

75 Animal preparation and signal generation and recording have been described elsewhere
76 (Burwood et al., 2017). Briefly, pigmented guinea pigs of similar weight (350-360 g) and both
77 sexes were anaesthetised with the neurolept anaesthetic technique (0.06 mg/kg body weight
78 atropine sulphate s.c., 30 mg/kg pentobarbitone i.p., 500 µl/kg Hypnorm i.m.). Additional
79 injections of Hypnorm were given every 40 minutes. Additional doses of pentobarbitone were
80 administered as needed to maintain a non-reflexive state. The heart rate was monitored with a
81 pair of skin electrodes placed on both sides of the thorax. The animals were tracheotomized
82 and artificially respired with a mixture of O₂/CO₂, and their core temperature was maintained
83 at 38°C with a heating blanket and a heated head holder. All procedures involving animals
84 were performed in accordance with UK Home Office regulations with approval from the
85 University of Brighton Animal Welfare and Ethical Review Body.

86 **Signal generation and recording**

87 The middle ear cavity of the ear used for the measurements and salicylate application was
88 opened to reveal the RW. Compound action potentials (CAPs) of the auditory nerve in response
89 to pure tone stimulation were measured from the cochlear bony ridge in the proximity of the
90 RW membrane using Teflon-coated silver wire coupled to laboratory designed and built
91 extracellular amplifier (James Hartley). Thresholds of the N1 peak of the CAP at different
92 frequencies which corresponds to different distances from the cochlear base (Greenwood,
93 1990) were estimated visually using 10 ms pure tone stimuli at a repetition rate of 10 Hz.

94 For acoustic stimulation sound was delivered to the tympanic membrane by a closed acoustic
95 system comprising two Bruel and Kjaer 4134 ½” microphones for delivering tones and a single
96 Bruel and Kjaer 4133 ½” microphone for monitoring sound pressure at the tympanum. The
97 microphones were coupled to the ear canal via 1 cm long, 4 mm diameter tubes to a conical
98 speculum, the 1 mm diameter opening of which was placed about 1 mm from the tympanum.
99 The speculum was sealed in the ear canal. The closed sound system was calibrated in situ for
100 frequencies between 1 and 50 kHz. Known sound pressure levels were expressed in dB SPL re
101 2×10^{-5} Pa.

102 All acoustic stimuli in this work were shaped with raised cosines of 0.5 ms duration at the
103 beginning and at the end of stimulation. White noise for acoustical calibration and tone
104 sequences for auditory stimulation were synthesised by a Data Translation 3010 board at 250
105 kHz and delivered to the microphones through low-pass filters (100 kHz cut-off frequency).
106 Signals from the acoustic measuring amplifier (James Hartley) were digitised at 250 kHz using
107 the same board and averaged in the time domain. Experimental control, data acquisition and
108 data analysis were performed using a PC with programmes written in MATLAB (MathWorks,
109 MA).

110 **Salicylate application**

111 5 µl of 100 mM sodium salicylate solution in Hanks’ Balanced Salt Solution were placed on
112 the RW using pipettes. The solution was removed from the RW using paper wicks to observe
113 the wash out effect.

114 **Generation of pressure oscillations in the ear canal**

115 A modified mouse ventilator MiniVent Type 845 (Hugo Sachs Elektronik, March, Germany)
116 was used to generate oscillating air pressure in the ear canal. Output of the ventilator was
117 connected and sealed to the closed acoustic system. The stroke frequency (4 Hz) and stroke
118 volume (150 µl) were the same for the all experiments reported. The stroke volume was
119 maximized to achieve maximum stapes displacement limited only by the crista stapedius.


120 **Recording of stapes vibrations**


121 Stapes vibrations were recorded using a CLV-2534 laser vibrometer (Polytec GmbH,
122 Waldbronn, Germany). The laser beam was focussed onto the stapes head. The output voltage


123 from the vibrometer was low-pass filtered at 100 kHz, with a sensitivity of 5 mm/s/V. Stapes
124 displacement was found by integrating the velocity responses off-line.

125 **RESULTS**

126 When inaudible low-frequency air pressure oscillations are presented at the ear canal, they are
127 transmitted to the stapes which causes back and forth cochlear fluid movements through the
128 scala vestibuli (SV) and ST (red arrows in **Figure 1A**). The RW works as a pressure relief
129 valve during these movements and moves in counter phase with the stapes because the cochlear
130 bony wall and fluid are poorly compressible. The poor compressibility results in the fluid
131 volume velocity along the SV and ST to be the same. Consequently, fluid linear displacement
132 and velocity are much higher in the narrow apical parts of the scalae than at the base.
133 Specifically, the apical ST cross-sectional area in guinea pigs is almost 20 times smaller than
134 in the basal cochlear region (it is almost 6 times smaller in humans) (Thorne et al., 1999). This
135 proportional increase in the fluid displacement and velocity will facilitate distribution of a drug,
136 which originally diffuses through the RW and oval window into the cochlear base, along the
137 entire cochlea. Due to the small diameter of the cochlear scalae, the fluid flow along them is
138 dominated by fluid viscosity (i.e. it occurs at low Reynolds numbers). Thus, the fluid flow is
139 laminar and turbulent mixing will not contribute to uniform drug distribution. Chaotic
140 mixing/advection, both transversal and longitudinal, is, however, observed for laminar fluid
141 flows in helical pipes (Jones et al., 1989; Nguyen, 2011) which can be further facilitated by
142 periodic changes of the flow direction (Ottino and Wiggins, 2004). Therefore, under specific
143 condition of cochlear stimulation, the chaotic advection may well be a major factor contributing
144 to the mixing of drugs along the ST and SV, which resemble helical pipes (**Figure 1A**).







147

148 The ability to distribute drugs uniformly along the entire cochlea spiral using relatively large,
149 low-frequency periodic displacement of fluid in the ST and SV (**Figure 1A**) was demonstrated
150 in our experiments with application of salicylate to the RW. Salicylate readily passes through
151 the RW (Borkholder et al., 2014; Sadreev et al., 2019). To monitor salicylate diffusion along
152 an intact guinea pig cochlea *in vivo*, we utilized the suppressive effect of salicylate on cochlear
153 amplification via block of the outer hair cell somatic motility (Russell and Schauz, 1995;
154 Hallworth, 1997). We measured elevation of the threshold response of the compound action
155 potential (CAP) of the auditory nerve caused by salicylate at different frequencies, which, due
156 to cochlear tonotopicity, corresponds to different distances from the RW (Greenwood, 1990).
157 Salicylate did not cause elevation of the CAP threshold responses for frequencies below 5 kHz,
158 which corresponds to about 45% of the total cochlear length from the base, when it diffused
159 through the cochlea passively (Sadreev et al., 2019). The calculated gradient of base-to-apex
160 salicylate concentration was about 13 orders of magnitude. When, however, placement of
161 salicylate solution on the RW was followed by cochlear pumping, i.e. by 5-minute cycles of
162 large-amplitude (80 μm peak-to-peak), low-frequency (4 Hz) stapes movements caused by

163 pressure oscillations in the ear canal, the CAP threshold was elevated throughout the entire 1
164 kHz - 30 kHz frequency range tested (**Figures 1B, 2A-F, 3**). This corresponds to about 75% of
165 the total cochlear length from the base (Greenwood, 1990). The technique had no observable
166 influence, compared to passive diffusion, on responses to RW salicylate application for
167 locations close to the RW at the base of the cochlea (27 kHz, **Figure 2A**). Cochlear pumping,
168 however, led to more rapid threshold elevation for locations which were distal and apical to the
169 RW, even if the maximal threshold elevations were similar for both experimental paradigms
170 (15 kHz, **Figure 2B**). The threshold elevation saturated after 4-5 cycles of stimulation even for
171 the low frequencies of the most apical locations (**Figure 1B, 2E-F**) where passive diffusion
172 produced no effect. Smaller threshold elevations at low frequencies were due only to the
173 reduced contribution of cochlear amplification to cochlear responses at these frequencies
174 (Sadreev et al., 2019, Robles and Ruggero, 2001) and, in fact, reached almost maximal possible
175 elevations for those frequencies (**Figure 3**).

176 **DISCUSSION**

177 Cochlea pumping at 4 Hz was chosen because the helicotrema (an opening between the ST and
178 SV at the cochlear apex, HT in **Figure 1A**) shunts fluid pressure at 4 Hz preventing
179 overstimulation of the cochlear sensory apparatus. *In our control experiments, 4 Hz large-*
180 *amplitude stimulation used alone, without salicylate, did not cause any elevation of the CAP*
181 *threshold during the same protocol of stimulation and, in fact, during continuous CP at 4 kHz*
182 *for 20 minutes.* Partial recovery of the CAP thresholds after washing out salicylate from the
183 RW (**Figure 1B**) provided confirmation that the integrity of the sensory cells was preserved.

184 A stapes displacement of 80 μm in our experiments corresponds to 1.6 mm linear displacement
185 of the fluid in the apical parts of ST, because in guinea pigs the apical ST cross-sectional area
186 is almost 20 times smaller (Thorne et al., 1999) than the stapes area (Sim et al., 2013) and both
187 the cochlear bony wall and fluid are poorly compressible. Therefore, while salicylate effect in
188 the most apical 25% of the cochlear length was not measured due to poor hearing sensitivity
189 of guinea pigs below 1 kHz, most of the fluid in this region was replaced by fluid from more
190 basal regions during a single cycle of cochlear pumping. Hence, estimates of salicylate
191 distribution derived for the basal regions are valid for the most apical 25% of the cochlea.

192 The tentative physical principles which govern the uniform distribution of salicylate along the
193 cochlea are universal and should be valid for the distribution of an arbitrary substance,
194 including nanoparticles, in the human cochlea. Salicylate was used in these initial experiments

195 because of its well-documented physiological effect which allows estimation of the drug
196 distribution along the intact cochlea. It was also used because it challenged the method of
197 cochlear pumping, being a difficult drug to distribute along the cochlea because it is cleared
198 rapidly from the ST (Sadreev et al., 2019). It is anticipated that drugs, which are better retained
199 in the ST, will be redistributed along the cochlea even more quickly and efficiently (Salt and
200 Ma, 2001; Sadreev et al., 2019).

201 **ETHICS STATEMENT**

202 All procedures involving animals were performed in accordance with UK Home Office
203 regulations with approval from the University of Brighton Animal Welfare and Ethical Review
204 Body.

205 **AUTHOR CONTRIBUTIONS**

206 A.L., N.Z., Y.Y. and I.R. conceived and designed the study. A.L. performed the experiments.
207 A.L. and I.S. analyzed experimental results. All authors contributed to analysis and discussion
208 of the results. A.L. and I.R. wrote the manuscript with contribution from all authors.

209 **FUNDING**

210 The research was funded by a grant from the Medical Research Council (MR/N004299/1).

211 **CONFLICT OF INTEREST STATEMENT**

212 A.L., N.Z. and Y.Y. are inventors on a United Kingdom Patent Application No. 1908260.1
213 submitted by The University of Brighton that covers method and device for substance delivery
214 to the inner ear. N.Z. is employed by the company Otophysica Ltd, Uckfield, UK. The
215 remaining authors declare that the research was conducted in the absence of any commercial
216 or financial relationships that could be construed as a potential conflict of interest.

217 **REFERENCES**

218 Borkholder, D. A., Zhu, X., and Frisina, R. D. (2014). Round window membrane intracochlear
219 drug delivery enhanced by induced advection. *J. Control. Release* 174, 171-176. doi:
220 10.1016/j.jconrel.2013.11.021

- 221 Burwood, G. W., Russell, I. J., and Lukashkin, A. N. (2017). Rippling pattern of distortion
222 product otoacoustic emissions evoked by high-frequency primaries in guinea pigs. *J. Acoust.*
223 *Soc. Am.* 142, 855-862. doi: 10.1121/1.4998584
- 224 Creber, N. J., Eastwood, H. T., Hampson, A. J., Tan, J., and O'Leary, S. J. (2018). A
225 comparison of cochlear distribution and glucocorticoid receptor activation in local and
226 systemic dexamethasone drug delivery regimes. *Hear. Res.* 368, 75-85. doi:
227 10.1016/j.heares.2018.03.018
- 228 Devare, J., Gubbels, S., and Raphael, Y. (2018). Outlook and future of inner ear therapy.
229 *Hear. Res.* 368, 127-135. doi: 10.1016/j.heares.2018.05.009
- 230 Greenwood, D. D. (1990). A cochlear frequency-position function for several species--29
231 years later. *J. Acoust. Soc. Am.* 87, 2592-2605. doi: 10.1121/1.399052
- 232 Grewal, A. S., Nedzelski, J. M., Chen, J. M., and Lin, V. Y. (2013). Dexamethasone uptake
233 in the murine organ of Corti with transtympanic versus systemic administration. *Journal of*
234 *Otolaryngology - Head & Neck Surgery* 42, 19. doi: 10.1186/1916-0216-42-19
- 235 Hallworth, R. (1997). Modulation of outer hair cell compliance and force by agents that
236 affect hearing. *Hear. Res.* 114, 204-212. doi: 10.1016/S0378-5955(97)00167-6
- 237 Hao, J., and Li, S. K. (2019). Inner ear drug delivery: Recent advances, challenges, and
238 perspective. *Eur. J. Pharm. Sci.* 126, 82-92. doi: 10.1016/j.ejps.2018.05.020
- 239 Imamura, S. I., and Adams, J. C. (2003). Distribution of gentamicin in the guinea pig inner
240 ear after local or systemic application. *J. Assoc. Res. Otolaryngol.* 4, 176-195. doi:
241 10.1007/s10162-002-2036-8
- 242 Jones, S. W., Thomas, O. M., and Aref, H. (1989). Chaotic advection by laminar flow in a
243 twisted pipe. *J. Fluid Mech.* 209, 335-357. doi: 10.1017/S0022112089003137
- 244 Mynatt, R., Hale, S. A., Gill, R. M., Plontke, S. K., and Salt, A. N. (2006). Demonstration of
245 a longitudinal concentration gradient along scala tympani by sequential sampling of
246 perilymph from the cochlear apex. *J. Assoc. Res. Otolaryngol.* 7, 182-193. doi:
247 10.1007/s10162-006-0034-y
- 248 Nguyen, N.-T. (2011). *Micromixers: fundamentals, design and fabrication.* William Andrew.

- 249 Nuttall, A. L., Ricci, A. J., Burwood, G., Harte, J. M., Stenfelt, S., Cayé-Thomasen, P., Ren,
250 T., Ramamoorthy, S., Zhang, Y., Wilson, T. and Lunner, T. (2018). A mechano-electrical
251 mechanism for detection of sound envelopes in the hearing organ. *Nat. Commun.* 9, 4175.
252 doi: 10.1038/s41467-018-06725-w
- 253 Nyberg, S., Abbott, N. J., Shi, X., Steyger, P. S., and Dabdoub, A. (2019). Delivery of
254 therapeutics to the inner ear: The challenge of the blood-labyrinth barrier. *Sci. Transl. Med.* 11,
255 eaao0935. doi: 10.1126/scitranslmed.aao0935
- 256 Ohyama, K., Salt, A. N., and Thalmann, R. (1988). Volume flow rate of perilymph in the
257 guinea-pig cochlea. *Hear. Res.* 35, 119-129. doi: 10.1016/0378-5955(88)90111-6
- 258 Ottino, J. M., and Wiggins, S.R. (2004). Introduction: mixing in microfluidics. *Philos. Trans.*
259 *A Math. Phys. Eng. Sci.*, 362, 923-935. doi: 10.1098/rsta.2003.1355
- 260 Patel, J., Szczupak, M., Rajguru, S., Balaban, C., and Hoffer, M. E. (2019). Inner Ear
261 Therapeutics: An Overview of Middle Ear Delivery. *Front. Cell. Neurosci.* 13, 261. doi:
262 10.3389/fncel.2019.00261
- 263 Piu, F., and Bishop, K. M. (2019). Local Drug Delivery for the Treatment of Neurotology
264 Disorders. *Front. Cell. Neurosci.* 13, 238. doi: 10.3389/fncel.2019.00238
- 265 Plontke, S. K., Biegner, T., Kammerer, B., Delabar, U., and Salt, A. N. (2008).
266 Dexamethasone concentration gradients along scala tympani after application to the round
267 window membrane. *Otol. Neurotol.* 29, 401-406. doi: 10.1097/MAO.0b013e318161aaae
- 268 Plontke, S. K., Mynatt, R., Gill, R. M., Borgmann, S., and Salt, A. N. (2007). Concentration
269 gradient along the scala tympani after local application of gentamicin to the round window
270 membrane. *Laryngoscope*, 117, 1191-1198. doi: 10.1097/MLG.0b013e318058a06b
- 271 Robles, L., and Ruggero, M.A. (2001). Mechanics of the Mammalian Cochlea. *Physiol. Rev.*
272 81, 1305-1352. doi: 10.1152/physrev.2001.81.3.1305
- 273 Russell, I. J., and Schauf, C. (1995). Salicylate ototoxicity: Effects on stiffness and
274 electromotility of outer hair cells isolated from the guinea pig cochlea. *Auditory Neurosci.* 1,
275 309-319.

- 276 Rybak, L. P., Dhukhwa, A., Mukherjea, D., and Ramkumar, V. (2019). Local Drug Delivery
277 for Prevention of Hearing Loss. *Front. Cell. Neurosci.* 13, 300. doi:
278 10.3389/fncel.2019.00300
- 279 Sadreev, I. I., Burwood, G. W. S., Flaherty, S. M., Kim, J., Russell, I. J., Abdullin, T. I. et al.
280 (2019). Drug Diffusion Along an Intact Mammalian Cochlea. *Front. Cell. Neurosci.* 13, 161.
281 doi: 10.3389/fncel.2019.00161
- 282 Saijo, S., and Kimura, R. S. (1984). Distribution of HRP in the inner ear after injection into
283 the middle ear cavity. *Acta Otolaryngol.* 97, 593-610. doi: 10.3109/00016488409132937
- 284 Salt, A. N., and Hirose, K. (2018). Communication pathways to and from the inner ear and
285 their contributions to drug delivery. *Hear. Res.* 362, 25-37. doi: 10.1016/j.heares.2017.12.010
- 286 Salt, A. N., and Ma, Y. (2001). Quantification of solute entry into cochlear perilymph
287 through the round window membrane. *Hear. Res.* 154, 88-97. doi: 10.1016/S0378-
288 5955(01)00223-4
- 289 Salt, A. N., and Plontke, S. K. (2009). Principles of local drug delivery to the inner ear.
290 *Audiol. Neurotol.* 14, 350-360. doi: 10.1159/000241892
- 291 Schilder, A. G. M., Su, M. P., Blackshaw, H., Lustig, L., Staecker, H., Lenarz, T., et al. (2019).
292 Hearing Protection, Restoration, and Regeneration: An Overview of Emerging Therapeutics
293 for Inner Ear and Central Hearing Disorders. *Otol. Neurotol.* 40, 559-570. doi:
294 10.1097/MAO.0000000000002194
- 295 Schuknecht, H. F. (1956). Ablation therapy for the relief of Meniere's disease. *Laryngoscope*
296 66, 859-859. doi: 10.1288/00005537-195607000-00005
- 297 Sim, J. H., Rösli, C., Chatzimichalis, M., Eiber, A., and Huber, A. M. (2013). Characterization
298 of Stapes Anatomy: Investigation of Human and Guinea Pig. *J. Assoc. Res. Otolaryngol.* 14,
299 159-173. doi: 10.1007/s10162-012-0369-5
- 300 Thorne, M., Salt, A. N., DeMott, J. E., Henson, M. M., Henson, O. W. Jr., and Gewalt, S. L.
301 (1999). Cochlear fluid space dimensions for six species derived from reconstructions of
302 three-dimensional magnetic resonance images. *Laryngoscope* 109, 1661–1668. doi:
303 10.1097/00005537-199910000-00021